Navigation Links
Curemark CEO To Deliver Keynote Address at the BioScience Vision Summit
Date:9/16/2013

RYE, N.Y., Sept. 16, 2013 /PRNewswire/ -- Curemark LLC announced that CEO Dr. Joan Fallon will deliver the keynote at BioForward's BioScience Vision Summit in Madison, WI on September 18.  Life science entrepreneurs from across the country will attend the event, which focuses on biotechnology partnerships and innovation.

Dr. Fallon's address, "Growth by Association: Winning through Public and Private Partnerships," will highlight the clear benefits of the collaboration of government and business with life sciences stakeholders. Dr. Fallon's Wisconsin speech comes on the heels of her speech to the White House Office of Technology and Science, attended by senior Obama Administration officials.  

Dr. Fallon stated that, "I'm delighted and honored to be asked to deliver the keynote address at such an important conference and looking forward to meeting thought leaders from across the life sciences sector."

"Wisconsin is a center of innovation for the biosciences, which is why this conference is extremely important. Patients want help, particularly for the large number of still-unmet medical needs.  We need novel solutions and new thinking to move biotechnology forward," Dr. Fallon continued.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com

Safe-Harbor Statements

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
2. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
3. Cardiovascular Drug Delivery - Technologies, Markets and Companies - Updated 2012 Report
4. PI USA Offers High-End Compact Rotation Stage; Delivers High Performance and Precision via Air Bearings and Torque Motor
5. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
6. Biotech & BioPharma Professionals: CA Board of Pharmacy Executive, Virginia Herold, to Deliver Keynote at BSMA Annual Biotechnology Conference Oct 8-9
7. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
8. PolyScience Performance Programmable Circulating Baths Deliver Ultra-Precise, Highly Customizable Performance
9. Bend Research Presents Drug Delivery Advancements at Controlled Release Society Annual Meeting
10. Vaginal Ring Provides “Radically New” Drug Delivery Platform for Health Issues, Including Infertility
11. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):